Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Article in English | MEDLINE | ID: mdl-26738003

ABSTRACT

The Gait Real-time Analysis Interactive Lab (GRAIL) is an instrumented multi-sensor platform based on immersive virtual reality for gait training and rehabilitation. Few studies have been included GRAIL to evaluate gait patterns in normal and disabled people and to improve gait in adults, while at our knowledge no evidence on its use for the rehabilitation of children is available. In this study, 4 children suffering from acquired brain injury (ABI) underwent a 5 session treatment with GRAIL, to improve walking and balance ability in engaging VR environments. The first and the last sessions were partially dedicated to gait evaluation. Results are promising: improvements were recorded at the ankle level, selectively at the affected side, and at the pelvic level, while small changes were measured at the hip and knee joints, which were already comparable to healthy subjects. All these changes also conveyed advances in the symmetry of the walking pattern. In the next future, a longer intervention will be proposed and more children will be enrolled to strongly prove the effectiveness of GRAIL in the rehabilitation of children with ABI.


Subject(s)
Brain Injuries/rehabilitation , Gait/physiology , Rehabilitation/methods , User-Computer Interface , Walking/physiology , Ankle/physiology , Child , Humans , Pelvis/physiology
2.
Heredity (Edinb) ; 102(3): 236-45, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18781168

ABSTRACT

So far, in maize, three classes of mutants involved in phytic acid biosynthesis have been isolated: lpa1, lpa2 and lpa3. In 2007, a gene tagging experiment performed by Shi et al. found that mutations in ZmMRP4 (multidrug resistance-associated proteins 4) gene cause lpa1 phenotype. In previous studies, we isolated and described a single recessive lpa mutation (originally named lpa241), which was allelic to the lpa1-1 mutant, and was consequently renamed lpa1-241. It showed a decrease in the expression of the myo-inositol (Ins)-3-phosphate synthase gene (mips1S). In this study, we present genetic and molecular analyses of the lpa1-241 mutation that indicate an epigenetic origin of this trait, that is, a paramutagenic interaction that results in meiotically heritable changes in ZmMRP4 gene expression, causing a strong pleiotropic effect on the whole plant. The use of a 5-Azacytidine treatment provided data suggesting an association between gene methylation and the lpa1-241 phenotype. To our knowledge, this is the first report of a paramutagenic activity not involving flavonoid biosynthesis in maize, but regarding a key enzyme of an important metabolic pathway in plants.


Subject(s)
Mutation , Phytic Acid/biosynthesis , Quantitative Trait, Heritable , Zea mays/genetics , Azacitidine/pharmacology , DNA Methylation , Gene Expression Regulation, Plant , Multidrug Resistance-Associated Proteins/genetics , Multidrug Resistance-Associated Proteins/metabolism , Phenotype , Plant Proteins/genetics , Plant Proteins/metabolism , Zea mays/drug effects , Zea mays/metabolism
3.
BJOG ; 114(7): 838-44, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17506789

ABSTRACT

OBJECTIVES: We aimed to determine the feasibility of conducting a randomised controlled trial (RCT) on the use of aromatherapy during labour as a care option that could improve maternal and neonatal outcomes. DESIGN: RCT comparing aromatherapy with standard care during labour. SETTING: District general maternity unit in Italy. SAMPLE: Two hundred and fifty-one women randomised to aromatherapy and 262 controls. METHODS: Participants randomly assigned to administration of selected essential oils during labour by midwives specifically trained in their use and modes of application. MAIN OUTCOME MEASURES: Intrapartum outcomes were the following: operative delivery, spontaneous delivery, first- and second-stage augmentation, pharmacological pain relief, artificial rupture of membranes, vaginal examinations, episiotomy, labour length, neonatal wellbeing (Apgar scores) and transfer to neonatal intensive care unit (NICU). RESULTS: There were no significant differences for the following outcomes: caesarean section (relative risk [RR] 0.99, 95% CI: 0.70-1.41), ventouse (RR 1.5, 95% CI: 0.31-7.62), Kristeller manoeuvre (RR 0.97, 95% CI: 0.64-1.48), spontaneous vaginal delivery (RR 0.99, 95% CI: 0.75-1.3), first-stage augmentation (RR 1.01, 95% CI: 0.83-1.4) and second-stage augmentation (RR 1.18, 95% CI: 0.82-1.7). Significantly more babies born to control participants were transferred to NICU, 0 versus 6 (2%), P = 0.017. Pain perception was reduced in aromatherapy group for nulliparae. The study, however, was underpowered. CONCLUSION: This study demonstrated that it is possible to undertake an RCT using aromatherapy as an intervention to examine a range of intrapartum outcomes, and it provides useful information for future sample size calculations.


Subject(s)
Aromatherapy/methods , Labor, Obstetric , Obstetric Labor Complications/prevention & control , Prenatal Care/methods , Feasibility Studies , Female , Humans , Pilot Projects , Pregnancy , Pregnancy Outcome , Prospective Studies
4.
Arch Ital Biol ; 143(2): 157-68, 2005 May.
Article in English | MEDLINE | ID: mdl-16106996

ABSTRACT

The two approaches presented here bypass postsynaptic receptors as indicators of quantal release, and thus they can provide information which is clearly distinct from that obtained with standard electrophysiological techniques. Indeed, the inherently variable responsiveness of the postsynaptic membrane makes it an unreliable indicator of presynaptic activity and this has fueled a lot of controversy, particularly in the area of synaptic plasticity. A major advantage of these two methods is their ability to detect changes at the single bouton level. This offers a lot of advantages including the possibility to study the functional role for exo-endocytosis but also plasticity against a background of great variability among a large number of synapses. The spatial resolving power of FM1-43 and anti-synaptotagmin antibodies may be valuable in future studies of spread of LTP between neighboring synapses and in the mapping the pattern of neuronal activity in complex networks of neurons.


Subject(s)
Central Nervous System/physiology , Microscopy, Fluorescence/methods , Presynaptic Terminals/physiology , Staining and Labeling/methods , Synaptic Transmission/physiology , Animals , Central Nervous System/ultrastructure , Fluorescent Antibody Technique/methods , Fluorescent Antibody Technique/trends , Fluorescent Dyes , Humans , Microscopy, Fluorescence/trends , Nerve Tissue Proteins/metabolism , Optics and Photonics/instrumentation , Presynaptic Terminals/ultrastructure , Staining and Labeling/trends
5.
Theor Appl Genet ; 107(6): 980-7, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14523526

ABSTRACT

Phytic acid, myo-inositol 1,2,3,4,5,6-hexakisphosphate, is the major storage compound of phosphorous (P) in plants, predominantly accumulating in seeds (up to 4-5% of dry weight) and pollen. In cereals, phytic acid is deposited in embryo and aleurone grain tissues as a mixed "phytate" salt of potassium and magnesium, although phytates contain other mineral cations such as iron and zinc. During germination, phytates are broken down by the action of phytases, releasing their P, minerals and myo-inositol which become available to the growing seedling. Phytic acid represents an anti-nutritional factor for animals, and isolation of maize low phytic acid ( lpa) mutants provides a novel approach to study its biochemical pathway and to tackle the nutritional problems associated with it. Following chemical mutagenesis of pollen, we have isolated a viable recessive mutant named lpa 241 showing about 90% reduction of phytic acid and about a tenfold increase in seed-free phosphate content. Although germination rate was decreased by about 30% compared to wild-type, developement of mutant plants was apparentely unaffected. The results of the genetic, biochemical and molecular characterization experiments carried out by SSR mapping, MDD-HPLC and RT-PCR are consistent with a mutation affecting the MIPS1S gene, coding for the first enzyme of the phytic acid biosynthetic pathway.


Subject(s)
Phytic Acid/metabolism , Seeds/physiology , Zea mays/genetics , Animals , Crops, Agricultural , Genotype , Humans , Molecular Structure , Mutation , Pedigree , Phenotype , Phosphates/metabolism , Phytic Acid/chemistry , Zea mays/cytology , Zea mays/metabolism
6.
Am J Hematol ; 55(2): 59-64, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9208999

ABSTRACT

Four hundred and ninety-three consecutive patients referred for arterial or venous thrombosis were screened for congenital and acquired abnormalities of blood coagulation predisposing to thrombosis, and were compared to 341 age- and sex-matched controls. The aim of the study was to determine the prevalence and clinical characteristics of resistance to activated protein C (APC), a defect shown to have different prevalences in different ethnic groups and to be associated with an increased risk of thrombosis. Seventy-three (15%) patients had both APC resistance and the 1691 G to A factor V gene mutation, compared to 6/341 (2%) controls. Seven patients had antithrombin deficiency (1.4%), 11 had protein C deficiency (2.2%), and 4 had protein S deficiency (0.8%). The relative risk of thrombosis in APC-resistant patients was 9.4. Resistance to APC was associated mainly with venous thrombosis, the most frequent being deep-vein thrombosis of the lower limbs. Fifty-eight percent of APC-resistant patients had an associated risk factor at the first thrombotic event: pregnancy and oral contraceptive intake were associated with the first thrombotic episode in 35% and 30% of women, respectively. APC resistance is the most frequent defect of blood coagulation in the general population and in the unselected thrombotic population studied by us.


Subject(s)
Blood Coagulation Disorders/physiopathology , Factor V/genetics , Protein C/metabolism , Thrombosis/physiopathology , Adult , Aged , Contraceptives, Oral/adverse effects , Enzyme Activation , Female , Humans , Male , Middle Aged , Point Mutation , Pregnancy , Pregnancy Complications, Hematologic , Protein C Deficiency , Protein S Deficiency/complications , Risk Factors
7.
Ann Intern Med ; 126(9): 707-11, 1997 May 01.
Article in English | MEDLINE | ID: mdl-9139557

ABSTRACT

BACKGROUND: Hypercoagulable states and triggering factors (surgery, trauma, immobilization, pregnancy, and use of oral contraceptives) are associated with an increased risk for deep venous thrombosis of the lower extremities. In contrast, risk factors for deep venous thrombosis of the upper extremities have not been identified. OBJECTIVE: To evaluate the prevalence of hypercoagulable states and triggering factors in patients with primary deep venous thrombosis of the upper extremities. DESIGN: Frequency-matched case-control study. SETTING: Hemophilia and thrombosis center at a university hospital. PATIENTS: 36 patients who had primary deep venous thrombosis of the upper extremities, 121 patients who had primary deep venous thrombosis of the lower extremities, and 108 healthy controls. Patients who had deep venous thrombosis of the lower extremities and study controls were frequency-matched by age, sex, geographic origin, and social status with patients who had deep venous thrombosis of the upper extremities. MEASUREMENTS: Resistance to activated protein C was evaluated by a clotting method based on the activated partial thromboplastin time. If test results were abnormal or borderline, DNA analysis for substitution in coagulation factor V gene was done. Antithrombin, protein C, protein S, antiphospholipid antibodies, and total plasma homocysteine levels were also measured. RESULTS: Prevalences of abnormalities of the natural anticoagulant system (9%) and hyperhomocysteinemia (6%) in patients who had deep venous thrombosis of the upper extremities were similar to prevalences of both factors in controls (6% and 7%, respectively) but lower than in patients who had deep venous thrombosis of the lower extremities (31% and 14%, respectively). Antiphospholipid antibodies were found only in patients who had venous thrombosis of the lower extremities (7%). The overall prevalence of hypercoagulable states in patients who had thrombosis of the upper extremities (15%) was similar to that in controls (12%) but was significantly lower than that in patients who had thrombosis of the lower extremities (56%). A recent history of strenuous exercise of muscles in the affected extremity was the most frequent triggering factor for patients who had deep venous thrombosis in the upper extremities (33%). CONCLUSIONS: This preliminary study indicates that the prevalence of hypercoagulable states is low in patients who have primary deep venous thrombosis of the upper extremities.


Subject(s)
Blood Coagulation Disorders/complications , Thrombosis/etiology , Adult , Arm , Case-Control Studies , Contraceptives, Oral/adverse effects , Female , Homocysteine/blood , Humans , Male , Middle Aged , Risk Factors , Thrombosis/blood
8.
Thromb Haemost ; 77(3): 440-3, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9065990

ABSTRACT

In 70-80% of cases, pulmonary embolism is the consequence of lower extremity deep vein thrombosis. It has been demonstrated that the most common coagulation defect predisposing to venous thrombosis, resistance to activated protein C (APC), is not associated with an increased risk for pulmonary embolism, but the evidence was based on a functional assay to diagnose APC resistance and no information about concomitant deep vein thrombosis was provided. The aim of our study was to evaluate the prevalence of factor V:Q506, the gene mutation responsible for APC resistance, in patients with symptomatic non-fatal pulmonary embolism, whether or not associated with deep vein thrombosis. Patients with uncomplicated deep vein thrombosis and healthy controls were investigated as comparison groups. The overall prevalence of factor V:Q506 in 106 patients with pulmonary embolism was 12.3%, lower than that found in 106 patients with deep vein thrombosis (22.6%, OR 0.5, 95% CI 0.2-1.0) but significantly higher than that found in 212 healthy subjects taken as controls (2.8%, OR 4.8, 95% CI 1.8-13.0). In the 41 patients with isolated pulmonary embolism, i.e., without the presence of deep vein thrombosis, the prevalence was 4.9%, similar to that in controls (OR 1.8, 95% CI 0.3-9.6), while in the remaining 65 patients with pulmonary embolism associated with deep vein thrombosis the prevalence was significantly higher (16.9%, OR 5.5, 95% CI 2.0-15.8). In conclusion, the prevalence of factor V:Q506 is high in patients with pulmonary embolism associated with deep vein thrombosis, whereas in patients with isolated pulmonary embolism it is similar to that found in control subjects. This intriguing finding is of difficult interpretation and needs confirmation by further studies.


Subject(s)
Factor V/genetics , Mutation , Pulmonary Embolism/genetics , Adolescent , Adult , Aged , DNA/analysis , Female , Humans , Male , Middle Aged , Prevalence , Protein C/metabolism , Pulmonary Embolism/blood , Pulmonary Embolism/complications , Thrombophlebitis/blood , Thrombophlebitis/complications , Thrombophlebitis/genetics
10.
Arterioscler Thromb ; 14(7): 1080-3, 1994 Jul.
Article in English | MEDLINE | ID: mdl-8018663

ABSTRACT

We determined the prevalence of hyperhomocyst(e)inemia before and 4 hours after a methionine load (3.8 g/m2) in 80 patients (25 mean and 55 women) who had had at least one verified episode of venous thromboembolism before the age of 40 years and in 51 healthy control subjects. No patient had any of the hemostatic abnormalities known to be associated with increased risk of venous thrombosis, and all had normal renal and liver function and no evidence of neoplastic disease. Hyperhomocyst(e)inemia was defined as fasting plasma homocyst(e)ine levels or absolute postload increments of homocyst(e)ine above the normal range. According to these diagnostic criteria, 15 patients (18.8%) and 1 control subject (1.9%) had hyperhomocyst(e)inemia. In 1 of these patients only, hyperhomocyst(e)inemia could be explained by low serum concentrations of vitamin B12 and folates. The family history for venous thromboembolism was positive for 7 of the 15 patients. Family studies, performed for eight kindreds, showed that for more than half of the studied probands the abnormality was inherited. This study indicates that moderate hyperhomocyst(e)inemia is associated with an increased risk of developing venous thromboembolism at a young age and that measurements of fasting and postmethionine plasma homocyst(e)ine levels may be useful in the evaluation of patients with juvenile venous thromboembolism, particularly if their family history suggests the presence of an inherited abnormality.


Subject(s)
Homocysteine/blood , Thromboembolism/blood , Administration, Oral , Adolescent , Adult , Female , Humans , Male , Methionine , Middle Aged , Pedigree , Prevalence , Pulmonary Embolism/blood , Pulmonary Embolism/complications , Thromboembolism/complications
11.
Int J Clin Lab Res ; 24(4): 220-2, 1994.
Article in English | MEDLINE | ID: mdl-7894048

ABSTRACT

In this prospective study, we evaluated the predictive value of activated partial thromboplastin time on day 8 post transplantation for event-free survival in patients who had had orthotopic liver transplants; both death and retransplantation within 6 months were the events considered. In a 4-year period, 109 patients had orthotopic liver transplants in our hospital, and 104 were eligible for the study since they survived and were not given new transplants within 8 days. The activated partial thromboplastin time was significantly longer in patients who survived event-free for less than 6 months than in those with longer event-free survivals. Kaplan-Meier curves showed that patients with normal activated partial thromboplastin times were nine times more likely to survive more than 6 months without events than patients with prolonged values. The positive predictive value of activated partial thromboplastin time for event-free survival was 88% and the negative predictive value was 54%, indicating that the test is useful for predicting patient outcome. We suggest that activated partial thromboplastin time be performed on day 8 post transplantation to predict the medium-term event-free survival.


Subject(s)
Liver Transplantation , Partial Thromboplastin Time , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Liver Transplantation/mortality , Liver Transplantation/statistics & numerical data , Male , Middle Aged , Predictive Value of Tests , Prognosis , Prospective Studies , Survival Rate
13.
Minerva Pediatr ; 41(11): 565-70, 1989 Nov.
Article in Italian | MEDLINE | ID: mdl-2622424

ABSTRACT

A computerized database for patients with juvenile rheumatoid arthritis (JRA) is presented. The program has been developed using PRIST (Patient Record Information System Tool), a flexible tool specifically oriented to clinical data management. The database consists of three main sections: the fixed record devoted to anamnestic data, the periodic record collecting the clinical, laboratory and instrumental data and the balance record devoted to a periodic balance of the disease course. The major advantages of our database are: time saving data handling, elastic procedures and easy retrospective data collection.


Subject(s)
Arthritis, Juvenile , Information Systems , Software , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...